Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 8/20 | 0.48 |
| ▸ | MAOB | P27338 | 8/20 | 0.48 |
| ▸ | ATP4A | P20648 | 1/20 | 0.48 |
| ▸ | ATP4B | P51164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4262042 | 0.99 | HPGDS (0.57) | HPGDSNPC1RAB9AHTR2CCYP19A1 | |
| Bromide SCHEMBL2972856 | 0.85 | NPC1 (0.62) | HPGDSNPC1RAB9ACYP19A1MAOA | |
| SCHEMBL4257174 | 0.84 | RAB9A (0.60) | HPGDSNPC1RAB9ACYP19A1MAOA | |
| Bromide SCHEMBL2984287 | 0.82 | HPGDS (0.51) | HPGDSNPC1RAB9AALDH1A1SMN1; SMN2 | |
| Bromide SCHEMBL2986096 | 0.81 | HPGDS (0.62) | HPGDSALDH1A1SMN1; SMN2 | |
| Bromide SCHEMBL2973216 | 0.81 | HPGDS (0.76) | HPGDSNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL24212820 | 0.81 | CYP19A1 (0.52) | NPC1RAB9ACYP19A1MAOAMAOB | |
| SCHEMBL4261970 | 0.81 | HPGDS (0.52) | HPGDSNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL2979648 | 0.81 | ALDH1A1 (0.51) | NPC1RAB9ACYP19A1MAOAMAOB | |
| SCHEMBL3772059 | 0.80 | HPGDS (0.64) | HPGDSALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786143-B2 | Thiazolyl piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1945635-B1 | THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-05-06 | — | — | EP | disclosed |
| EP-1945635-A2 | THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007020213-A2 | THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070043083-A1 | Thiazolyl piperidine derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043083-A1 | Thiazolyl piperidine derivatives | HRH3, HRH4, H1-3 | HPGDS 658/4885NPC1 807/4885RAB9A 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.